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Abstract 
Purpose: The tolerability and efficacy of simeprevir in combination with peginterferon and ribavirin in patients 
infected with hepatitis C virus (HCV) genotype 1 under actual clinical conditions were investigated.
Methods: A total of 176 patients with chronic HCV genotype 1 infection were treated with simeprevir for 12 weeks 
plus Peg-IFN/RBV for 24 weeks. Overall, 107 (60.7 %) patients were aged 60 years or more, and 16 (9 %) patients were 
aged 70 years or more. Treatment discontinuation, sustained virological response 12 (SVR12), and viral relapse were 
evaluated and compared between younger patients and elderly patients.
Results: The rates of undetectable HCV RNA at the end of treatment were 95.8, 100 and 93.1 % in treatment-naïve, 
prior relapse, and prior non-responders, respectively. However, the rates of SVR12 were 82.4, 88.2 and 69.2 %, respec-
tively. Especially in prior non-responders, viral relapse was relatively frequent. Treatment discontinuation and SVR12 
were not different between patients aged <70 and ≥70 years, but viral relapse after completing treatment was signifi-
cantly more frequent in patients aged ≥70 years (p = 0.012).
Conclusions: In simeprevir with peginterferon and ribavirin therapy, viral relapse was relatively frequent. Especially in 
elderly patients, the relapse rate was high after completing treatment, instead of low frequency of discontinuation by 
the adverse events.
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Background
Hepatitis C virus (HCV) infection is a major pub-
lic health concern. About 150 million individuals are 
infected worldwide, and every year, 3–4 million indi-
viduals become infected with the virus (European Asso-
ciation for the Study of the Liver 2011; Manns and von 
Hahn 2013). Japan has one of the highest rates of HCV 
infection worldwide, and around 2 million people are 
estimated to be infected, with the majority being infected 
with HCV genotype 1b (Chung et  al. 2010). Chronic 
infection and liver cirrhosis with HCV are major causes 
of liver disease (Lavanchy 2009), and hepatocellular car-
cinoma is a leading cause of cancer mortality in Japan, 
with more than 70 % of the cases related to HCV infec-
tion (Yuen et al. 2009).
The goal of chronic HCV infection treatment is 
virus eradication, to prevent progression to cirrhosis 
and hepatocellular carcinoma. Combination therapy 
with peginterferon (Peg-IFN) and ribavirin (RBV) for 
48–72  weeks has been standard care for HCV geno-
type 1 infection for many years (Editors of the Drafting 
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Committee for Hepatitis Management Guidelines: 
The Japan Society of Hepatology 2013; Ghany et  al. 
2011), resulting in sustained virologic response (SVR) 
in approximately 50  % of patients (Kuboki et  al. 2007; 
Manns et al. 2001).
The development of direct-acting antiviral agents 
(DAAs), including protease inhibitors (PIs), represents a 
major breakthrough in the treatment of chronic HCV infec-
tion. The addition of PI to Peg-IFN and RBV has markedly 
improved treatment outcomes in both treatment-naïve and 
treatment-experienced patients (Bacon et al. 2011; Hayashi 
et al. 2012; Jacobson et al. 2011; Kumada et al. 2012). How-
ever, first-generation HCV PIs, such as telaprevir and 
boceprevir, are associated with multiple daily dosing and 
the potential for adverse events, including anemia, rash, 
and renal dysfunction (Poordad et al. 2011; Zeuzem et al. 
2011), leading to high rates of treatment discontinuation 
(Hayashi et al. 2012; McHutchison et al. 2009).
Simeprevir (TMC435) is a once-daily, oral HCV PI, with 
potent antiviral activity against HCV genotype 1, as well as 
against genotypes 2 and 4–6, although the efficacy against 
genotype 2 has been demonstrated only in vitro (Reesink 
et  al. 2010; Moreno et  al. 2012). In international phase 3 
studies, simeprevir combined with Peg-IFN and RBV has 
shown good tolerability and high SVR rates in both treat-
ment-naïve (Jacobson et  al. 2014; Manns et  al. 2014) and 
treatment-experienced patients (Forns et  al. 2014; Reddy 
et al. 2015). In these studies, almost all treated patients were 
genotype 1 (1a: 41–56  %, 1b: 44–58  %), and 7.0–15.6  % 
of patients had liver cirrhosis. Japanese phase 3 studies of 
simeprevir combined with Peg-IFN and RBV have been 
reported in treatment-naïve patients (CONCERTO-1, 4) 
(Hayashi et al. 2014; Kumada et al. 2015), non-responders 
(CONCERTO-2), and relapsers (CONCERTO-3) to previ-
ous IFN-based therapy (Izumi et  al. 2014). In these Japa-
nese studies, almost all treated patients were genotype 1b, 
and no patients with liver cirrhosis were included.
However, in Japan, after these clinical trials, the tolera-
bility and efficacy in patients under real-world conditions 
have not been reported. Additionally, in the CONCERTO 
1–4 study, the eligible patients were younger than 
70 years, even though in Japan, the percentage of elderly 
patients with hepatitis C virus infection is high (Tanaka 
et  al. 2004, 2011). In this study, efficacy and treatment 
discontinuation for adverse events of simeprevir/Peg-
IFN/RBV therapy were evaluated in actual clinical prac-




A total of 176 patients with chronic HCV genotype 
1 infection and plasma HCV RNA of 5.0  log10IU/mL 
or more at screening were treated with simeprevir for 
12  weeks plus Peg-IFN/RBV for 24  weeks at 10 hospi-
tals belonging to the Ehime Kan-en Network (EKEN 
net; Ehime University Hospital, Matsuyama Red Cross 
Hospital, Ehime Prefectural Central Hospital, Uwajima 
City Hospital, Saiseikai Imabari Hospital, Matsuyama 
Shimin Hospital, Ehime Prefectural Imabari Hospital, 
Shiritsu Oozu Hospital, Ehime Prefectural Niihama Hos-
pital, and National Hospital Organization Ehime Medical 
Center). The Ethics Committee of Ehime University Hos-
pital approved the study protocol (approval ID 1411010), 
which conformed to the ethical guidelines of the Decla-
ration of Helsinki amended in 2008. Written, informed 
consent was obtained from each patient.
Exclusion criteria included liver cirrhosis or hepatic 
failure, liver diseases of non-HCV etiology, co-infection 
with non-genotype 1 HCV, hepatitis B virus, HIV-1 or 
HIV-2, and any other clinically significant disease, organ 
transplant, or defined obvious laboratory abnormalities 
at screening, as well as a history of hepatocellular carci-
noma within 5 years before study entry.
Treatment administration
Simeprevir (Janssen Pharmaceutical K.K., Tokyo, Japan) 
100 mg was administered orally once daily as a single cap-
sule. Simeprevir dose adjustments were not permitted. 
Two kinds of Peg-IFN/RBV were administered, namely 
Peg-IFN α-2a (Pegasys®, Chugai Pharmaceutical Co. Ltd, 
Tokyo, Japan) and RBV (Copegus®, Chugai Pharmaceuti-
cal Co. Ltd) or Peg-IFN α-2b (PegIntron®, Merck Sharp & 
Dohme, Whitehouse Station, NJ, USA) and RBV (Rebe-
tol®, Merck Sharp & Dohme). Peg-IFN α-2a was admin-
istered by subcutaneous injection (180 μg once weekly), 
and Peg-IFN α-2b was administered by subcutaneous 
injection (1.5 μg/kg body weight). RBV was administered 
as oral tablets (600–1000 mg total daily dose, depending 
on body weight). Dose changes, temporary interruptions, 
or discontinuation of Peg-IFN and RBV had to be con-
ducted in accordance with the manufacturer’s prescrib-
ing information.
Patients stopped simeprevir if they experienced any 
of the following: grade 4 elevation of total bilirubin or 
aspartate transaminase; grade 3/4 skin events/aller-
gic reactions; or worsening of hepatic disease. All study 
medications were stopped if patients experienced grade 
4 adverse events or laboratory abnormalities that were 
not considered to be related to simeprevir specifically 
or were not expected toxicities of Peg-IFN/RBV or HCV 
infection or if patients experienced worsening of hepatic 
disease.
Additionally, all study medications were stopped if 
the following defined virologic stopping criteria were 
met: <2  log10IU/mL reduction in HCV RNA at week 12 
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relative to baseline, or HCV RNA levels of more than 
2 log10IU/mL at week 12.
Study assessments
Plasma HCV RNA was quantified at screening at base-
line, and at 1, 2, 3, 4, 6, 8, 12, 24, 28 and 36 weeks using 
the Roche COBAS® TaqMan® HCV Auto assay system 
(Roche Molecular Diagnostics, Pleasanton, CA, USA) 
with a lower limit of quantification of 1.2 log10IU/mL.
The major efficacy end-point was the proportion of 
patients with undetectable HCV RNA at the end of treat-
ment and 12  weeks after the last treatment (SVR12). 
Other efficacy end-points included the proportion of 
patients with: undetectable HCV RNA at the end of 
treatment (EOT); undetectable HCV-RNA at the end of 
treatment and 4  weeks after the last treatment (SVR4); 
increase of >1  log10IU/mL in plasma HCV RNA level 
from the lowest level reached or plasma HCV RNA level 
>2.0  log10IU/mL in patients whose plasma HCV RNA 
level had previously been <1.2  log10IU/mL detectable or 
undetectable (viral breakthrough); detectable or quantifi-
able plasma HCV RNA during the post-treatment follow-
up period in patients who had undetectable plasma HCV 
RNA at the end of treatment (viral relapse); and the pro-
portion of patients who discontinued treatment due to 
adverse events or virologic stopping criteria.
Statistical analysis
Differences were evaluated using the χ2-test, Student’s t 
test, or Welch’s t test. Factors that were not normally dis-
tributed were evaluated by Welch’s t test. Predictors of 
SVR12 and viral relapse after treatment completion were 
evaluated using multivariate logistic regression analyses. 
Odds ratios (ORs) and 95  % confidence intervals were 
also calculated. All p values <0.05 on two-tailed testing 
were considered significant. Data were statistically ana-
lyzed using SPSS software ver. 18.
Results
Patients
This was a prospective, multicenter study. In total, 176 
patients received treatment; 85 patients were treatment-
naïve, and 90 patients were treatment-experienced. In 
treatment-experienced patients, 51 patients were prior 
relapsers (patients who had undetectable levels of HCV 
RNA at the last assessment while on IFN-based therapy 
and subsequent detectable levels of HCV RNA within 
12  months from their last treatment), 26 patients were 
prior non-responders (patients who did not achieve 
undetectable HCV RNA on prior IFN-based therapy), 
and there was no prior treatment information for the 
remaining 12 patients. Demographic and disease char-
acteristics at baseline are shown in Table 1. The patients’ 
median age was 62  years (range 28–78  years); 107 
(60.7 %) patients were aged 60 years or more, and 16 (9 %) 
patients were aged 70  years or more. IL28B rs8099917 
polymorphisms were determined in 91 patients; 69 
patients were major allele TT, and 22 patients were minor 
allele TG/GG.
Virologic response
The rates of HCV RNA negative conversion during the 
treatment period in patients grouped according to past 
treatment experience are shown in Fig. 1 (ITT analysis); 
most patients in all groups had achieved levels below 
the lower limit of quantification. Non-responders had 
slightly lower rates of HCV RNA negative conversion at 
each time point, but significant differences were not seen.
The EOT response, SVR4 response, and SVR12 
response are shown in Fig. 2. In all patients, EOT, SVR4, 
and SVR12 responses were 96.0, 88.6 and 81.8 %, respec-
tively. There was a relatively high frequency of viral 
relapse. The viral relapse rate was higher in non-respond-
ers than in treatment-naïve patients or relapsers.
Treatment discontinuation
Treatment discontinuation was seen in 20 patients 
(11.3  %). The reasons for discontinuation are shown in 
Table  2. Viral breakthrough was seen in three patients, 
and two patients stopped treatment according to the 
virologic stopping criteria. Three of these five patients 
had a mutation in the HCV NS3 Protease domain at 
Table 1 Clinical and  virological characteristics of  patients 
with HCV infection
ALT alanine aminotransferase, AST aspartate aminotransferase, HCV hepatitis C 
virus, SNP single nucleotide polymorphism, Peg-IFN peginterferon, RBV ribavirin
Sex (male/female) 95/81
Age (years) 62 (28–78)
AST (IU/L) 43.5 (18–217)
ALT (IU/L) 48.0 (11–225)
Total bilirubin (mg/dL) 0.8 (0.1–2.7)
Hemoglobin (g/dL) 14.5 (10.1–18.3)
White blood cells (/µL) 4905 (2100–9610)
Platelet count (×104/µL) 15.3 (5.9–28.0)
HCV RNA (log copies/mL) 6.5 (5.0–7.8)
IL28B genotype (SNP8099917) (TT/non-TT) 69/22
HCV Core aa70 (wild/mutant) 38/13




Prior therapy (IFN only/IFN + RBV/Peg-IFN/Peg 
IFN + RBV/teraprevir/Others)
12/7/5/49/3/12
Histological fibrosis (METAVIR score) (F0/F1/F2/F3/ 
F4/ND)
1/28/34/30/4/79
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position 168 (D168V, D168E, and D168A, respectively) at 
the end of treatment or at viral relapse.
Treatment discontinuation and efficacy in elderly patients
In Japan, the percentage of elderly patients with hepati-
tis C virus infection is high. In fact, 60.7  % of the pre-
sent patients were aged 60 years or more, and 9 % of the 
patients were aged 70 years or more. The rates of treat-
ment discontinuation and SVR12 achievement were 
compared between patients aged 60  years or more and 
patients aged <60  years. Similarly, the rates of treat-
ment discontinuation and SVR12 achievement were 
compared between patients aged 70  years or more and 
patients aged <70 years. The rates of treatment discon-
tinuation and SVR12 achievement were not significantly 
different between patients aged 60  years or more and 
patients aged <60  years (p =  0.225, p =  0.556, respec-
tively) (Fig. 3a). Similarly, the rates of treatment discon-
tinuation and SVR12 achievement were not significantly 
different between patients aged 70  years or more and 
patients aged <70  years (p =  0.090, p =  0.081, respec-
tively) (Fig. 3b).
As mentioned above, there was a relatively high fre-
quency of viral relapse after completion of 24 weeks ther-
apy. Thus, the rates of viral relapse after completion of 
24  weeks therapy were also compared between patients 
aged 60 years or more and patients aged <60 years, and 
between patients aged 70 years or more and patients aged 
<70 years. The rates of viral relapse after treatment com-
pletion were not significantly different between patients 
aged 60  years or more and patients aged <60  years 
(p = 0.49) (Fig. 4a). However, viral relapse after treatment 
completion was significantly more frequent in patients 
aged 70 years or more than in those aged <70 years (41.6 
vs 12.5 %, p = 0.018) (Fig. 4b).
Predictors of SVR12 achievement
Factors that might contribute to SVR achievement 
were evaluated (Table  3). Potential predictive fac-
tors associated with SVR12 included age (70  years or 
more/<70  years), sex, ALT, platelet count, AFP, HCV-
RNA, IL28B rs8099917 polymorphisms (TT/non-TT), 
HCV Core aa70 (wild/mutant), HCV Core aa91 (wild/
mutant), treatment-naïve/treatment-experienced, non-
responders to past treatment/others, Peg-IFN adherence, 
Fig. 1 The proportion of HCV RNA negative conversion at each 
time point after treatment start (ITT analysis). The black line shows 
the proportion of HCV RNA negative conversion in all patients. The 
gray line shows that in treatment-naïve patients, the black dotted line 
shows that in prior relapsers, and the gray dotted line shows that in 
prior non-responders. Non-responders have slightly lower rates of 
HCV RNA negative conversion at each time point, but no significant 
differences are seen
Fig. 2 The proportions of EOT, SVR4, and SVR12 achievement in all 
patients, treatment-naïve patients, relapsers, and non-responders are 
shown. EOT, undetectable HCV RNA at the end of treatment; SVR4, 
undetectable HCV-RNA at the end of treatment and 4 weeks after the 
last treatment; SVR12, undetectable HCV-RNA at the end of treatment 
and 12 weeks after the last treatment
Table 2 Reasons for  discontinuing treatment with  sime-
previr plus Peg-IFN/RBV
Reason for discontinuation No. 
of patients
Viral breakthrough 3
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and RBV adherence. HCV NS3 Q80  K status, which 
has been reported as a predictor of simeprevir failure, 
was tested in 38 patients, and only 1 (2.6 %) patient had 
Q80  K; thus, this was not evaluated as a predictive fac-
tor. It was found that the presence of IL28B rs8099917 
polymorphisms was the only predictive factor (p = 0.02). 
Platelet count, HCV core aa70, and non-responders 
tended to be associated with SVR12 achievement, but 
they were not significant. Multivariate analysis was per-
formed using the factors whose p values were <0.1 on 
univariate analyses (age 70  years or more/<70  years, 
platelet count, HCV-RNA, IL28B polymorphisms, HCV 
core aa 70, non-responders to past treatment/others). 
Only IL28B polymorphism (TT vs non-TT, odds ratio: 
0.145, p  =  0.029) was identified as a significant factor 
(Table 4).
Predictors of viral relapse after treatment completion
In simeprevir/Peg-IFN/RBV therapy, since viral relapse 
after completion of 24  weeks of therapy was frequent, 
an attempt was made to identify the predictors of viral 
relapse after treatment completion (Table  5). Potential 
predictive factors associated with SVR12 included age 
(age 70 years or more/<70 years), sex, ALT, platelet count, 
AFP, HCV-RNA, IL28B rs8099917 polymorphisms (TT/
non-TT), HCV Core aa70 (wild/mutant), HCV Core aa91 
(wild/mutant), treatment-naïve/treatment-experienced, 
non-responders to past treatment/others, Peg-IFN 
adherence, and RBV adherence. Age 70  years or more, 
IL28B rs8099917 polymorphisms, and platelet count 
were identified as predictive factors (p  =  0.018, 0.012, 
0.023, respectively). Multivariate analysis was conducted 
using the factors whose p values were <0.1 on univariate 
Fig. 3 The proportions of treatment discontinuation and SVR12 achievement in patients aged 60 years or more and patients aged <60 years (a). 
The proportions of treatment discontinuation and SVR12 achievement in patients aged 70 years or more and patients aged <70 years (b). No 
significant differences are seen between younger and elderly patients
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analyses (age 70 years or more/<70 years, platelet count, 
IL28B polymorphisms, non-responders to past treat-
ment/others). Age (age 70  years or more vs <70  years, 
odds ratio: 15.1, p =  0.037) and IL 28B polymorphisms 
(TT vs non-TT, odds ratio: 6.29, p =  0.022) were iden-
tified as significant factors (Table  6). The factor age 
70 years or more had the highest odds ratio for predicting 
viral relapse after treatment completion.
Discussion
In patients treated with just Peg-IFN and ribavirin, IL28B 
genotype (non-TT) and advanced fibrosis are associated 
with a low rate of SVR (Tanaka et al. 2009; Manns et al. 
2001; Fried et al. 2002). In an international study of sime-
previr and Peg-IFN/Ribavirin, simeprevir treatment also 
resulted in higher SVR12 in patients with advanced fibro-
sis than just Peg-IFN and ribavirin (Jacobson et al. 2014; 
Fig. 4 The proportions of viral relapse after 24-week therapy comple-
tion. There is no significant difference between patients aged 60 years 
or more and patients aged <60 years (a). However, viral relapse is 
more frequent in patients aged 70 years or more than in patients 
aged <70 years (b) (41.6 vs 12.5 %, p = 0.018)
Table 3 Factors associated with SVR12 achievement
Data are expressed as mean ± standard deviation
SVR sustained virological response, ALT alanine aminotransferase, AFP 
α-fetoprotein, HCV hepatitis C virus, Peg-IFN peginterferon, RBV ribavirin
SVR12 Non-SVR12 p value
Sex (male/female) 82/62 13/19 0.11
Age 70 years or more/<70 years 134/10 26/6 0.08
ALT (U/L) 62.5 ± 45.9 64.9 ± 36.4 0.81
Platelet count (×104/µL) 15.8 ± 4.7 14.1 ± 4.9 0.08
AFP (ng/mL) 12.3 ± 34.4 16.0 ± 19.4 0.56
HCV-RNA (log copies/mL) 6.4 ± 0.68 6.6 ± 0.58 0.10
IL28B (TT/non-TT) 61/14 8/8 0.02
HCV Core aa70 (wild/mutant) 35/9 3/4 0.06
HCV Core aa91 (wild/mutant) 26/17 6/2 0.69
Treatment naïve/re-treatment 70/73 15/17 0.84
Non-responders/others 18/115 8/21 0.09
Peg-IFN adherence (%) 88.6 ± 22.4 78.6 ± 39.1 0.18
RBV adherence (%) 82.3 ± 22.4 76.7 ± 45.1 0.50
Histological fibrosis (F0-2/F3-4) 55/28 8/6 0.55
Table 4 Independent factors associated with  SVR12 
achievement on multiple logistic regression analysis
CI confidence interval
Odds ratio 95 % CI p value
IL28B (TT/non-TT) 0.145 0.026-0.822 0.029
Table 5 Factors associated with  viral relapse after  treat-
ment completion
Data are expressed as mean ± standard deviation
SVR sustained virological response, ALT alanine aminotransferase, AFP 
α-fetoprotein, HCV hepatitis C virus, Peg-IFN peginterferon, RBV ribavirin
Viral relapse SVR12 p value
Sex (male/female) 9/14 73/60 0.18
Age 70 years or more/<70 years 5/18 7/126 0.018
ALT (U/L) 62.6 ± 38.0 63.6 ± 46.9 0.92
Platelet count (×104/µL) 13.5 ± 4.5 15.9 ± 4.6 0.023
AFP (ng/mL) 16.6 ± 21.8 12.3 ± 35.4 0.58
HCV-RNA (log copies/mL) 6.6 ± 0.57 6.4 ± 0.69 0.14
IL28B (TT/non-TT) 4/6 57/14 0.012
HCV Core aa70 (wild/mutant) 1/2 33/9 0.14
HCV Core aa91 (wild/mutant) 3/1 24/17 0.64
Treatment naïve/re-treatment 10/13 66/66 0.65
Non-responders/others 6/17 16/106 0.10
Peg-IFN adherence (%) 88.6 ± 19.5 91.8 ± 18.6 0.46
RBV adherence (%) 90.6 ± 43.9 84.8 ± 20.7 0.33
Histological fibrosis (F0-2/F3-4) 7/6 52/25 0.35
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Manns et al. 2014; Forns et al. 2014). In the present study, 
platelet count and histological fibrosis did not affect the 
rate of SVR12. In these international studies, since the 
difference in SVR12 according to IL28B polymorphism 
was substantially smaller than in the placebo group, 
the correlation between IL28B genotype and efficacy of 
simeprevir was smaller than for just Peg-IFN/ribavirin 
therapy. In a Japanese study, the results of the subgroup 
analysis by IL28B polymorphism also showed that there 
were no significant differences in efficacy according to 
this genotype (Hayashi et  al. 2014; Kumada et  al. 2015; 
Izumi et  al. 2014). On the other hand, in the present 
study, only IL28B genotype was a factor affecting SVR12. 
Though in the past clinical studies of simeprevir therapy 
the median age of patients was in the forties or fifties, 
that of the present patients was 62  years, and patients 
over 70 years were also included, which would be the rea-
son for the difference in the effect on treatment efficacy 
between the present results and those of past studies. In 
Japanese actual clinical practice, the proportion of elderly 
patients is high, so the present results should be taken 
into account.
The present study showed that, especially in prior 
non-responders, there was a relatively high frequency 
of viral relapse (p =  0.060 compared with prior relaps-
ers). This result agreed with past studies; for example, 
in CONCERT-2 (prior non-responders), viral relapse 
was seen in 38.6  % compared to 8.2  % in CONCERT-3 
(prior relapsers). In the past reports, the factors involved 
in viral relapse after treatment completion were not ana-
lyzed; therefore, these factors were examined in the pre-
sent study. It was found that low platelet count and IL28B 
SNP8099917 non-TT genotype were the significant risk 
factors for viral relapse. Moreover, patients aged over 
70  years had a significantly higher frequency of viral 
relapse after treatment completion. In the present study, 
the number of patients aged over 70 years was small, so 
the result must be viewed in that light. However, multi-
variate analysis indicated that age over 70  years was an 
independent contributing factor to viral relapse after 
treatment completion. These data indicate that, for sup-
pression of viral relapse, the treatment effect of Peg-IFN/
ribavirin is important, because hepatic fibrosis, IL28B 
genotype, and age have previously been reported as 
factors affecting SVR in Peg-IFN/ribavirin therapy (Tan-
aka et al. 2009; Manns et al. 2001; Fried et al. 2002; Dien-
stag and McHutchison 2006).
Some mutations, such as D168E/T/V, Q80R/K, and 
R155K, have been previously described in HCV genotype 
1b after exposure to simeprevir in  vitro and in clinical 
studies (Hayashi et al. 2014; Lenz et al. 2010; Fried et al. 
2013). Additionally, the majority of patients with viral 
breakthrough or relapse had emerging mutations in the 
HCV NS3 protease domain. These mutations were mostly 
at position 168 (Lenz et al. 2010). In the present patients 
at treatment start, only one of 40 tested patients had a 
position 80 mutant, and all 40 tested patients were wild 
type at position 168 of the HCV NS3 protease domain. 
In the present study, viral breakthrough was seen in three 
patients, and two patients stopped treatment according 
to virologic stopping criteria. Three of these four patients 
had mutations in the HCV NS3 Protease domain at posi-
tion 168 (D168V, D168E, D168A, respectively) at the end 
of treatment or viral relapse. Unfortunately, these muta-
tions could not be examined in viral relapse patients.
In studies of first-generation protease inhibitors, rates 
of treatment discontinuation due to severe adverse 
events have been reported to be 10–20  % (Bacon et  al. 
2011; Hayashi et al. 2012; Jacobson et al. 2011; Kumada 
et al. 2012; Poordad et al. 2011). However, in simeprevir 
with Peg-IFN/ribavirin therapy, treatment discontinu-
ations were much less frequent, at 3–5 % (Hayashi et al. 
2014; Kumada et  al. 2015; Izumi et  al. 2014). Manns 
et  al. (2015) reported a pooled safety analysis from 
international phase IIb and III studies. In this report, 
most adverse events were grade 1/2, and most grade 3/4 
adverse events occurred in <5.0 % of patients. Moreover, 
tolerability did not vary with histological hepatic fibro-
sis. In the present study, the rate of treatment discon-
tinuation was not different between patients aged <60 
and ≥60  years, and even between those aged <70 and 
≥70 years. These results mean that simeprevir therapy is 
well tolerated even in the actual clinical setting.
The combination of simeprevir and other direct-acting 
antivirals such as sofosbuvir as an HCV NS5B inhibitor 
is expected to be the treatment option for patients with 
chronic HCV genotype 1 infection by providing inter-
feron-free treatment (Schinazi et al. 2014). Efficacy of the 
interferon-free combination of simeprevir and sofosbuvir, 
with or without ribavirin, in patients with HCV genotype 
1 infection was reported to be more than 90  % (SVR12 
rate) (Lawitz et al. 2014). Moreover, although direct-act-
ing antiviral combinations in an interferon-free regimen 
would be main stream in the future, Peg-IFN and ribavi-
rin-based treatment could remain the standard of care in 
parts of the world in which the very high treatment costs 
of direct-acting antiviral interferon-free regimens would 
Table 6 Independent factors associated with viral relapse 
after treatment completion on multiple logistic regression 
analysis
CI confidence interval
Odds ratio 95 % CI p value
Age 70 years or more/<70 years 15.1 1.18–194 0.037
IL28B (TT/non-TT) 6.29 1.29–30.5 0.022
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be prohibitive. Then, the present data of simeprevir with 
Peg-IFN and ribavirin in the actual clinical setting would 
be valuable.
In conclusion, in simeprevir with peginterferon and 
ribavirin therapy, both efficacy and tolerability are good, 
even in elderly patients, but viral relapse after complet-
ing treatment was high in patients aged over 70  years. 
Patients <70 years old and those discontinuing previous 
DAAs would be suitable for this treatment.
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